MUTATED FACTOR X POLYPEPTIDES AND USES THEREOF FOR THE TREATMENT OF HAEMOPHILIA

European Patent Office Patent

APP PUB NO EP-3242936-A1
SERIAL NO

16700156

Stats

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide wherein the heavy chain comprises at least one mutation selected from the group consisting of: - the mutation which consists of the substitution of the glutamic acid residue (E) at position 255 of Seq. ID No. 1 by a glutamine residue (Q), an asparagine residue (N), a serine residue (S), an alanine residue (A), or a tyrosine residue (Y); - the mutation which consists of the substitution of the glutamic acid residue (E) at position 256 of Seq. ID No. 1 by a glutamine residue (Q); and - the mutation which consists of the substitution of the glutamic acid residue (E) at position 258 of Seq. ID No. 1 by a glutamine residue (Q);

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE)FR

International Classification(s)

Inventor(s)

Inventor Name Address
CHRISTOPHE OLIVIER INSERM U 1176 - PARIS-SACLAY 80 RUE DU GÉNÉRAL LECLERC 94276 LE KREMLIN-BICÊTRE 94276
DENIS CECILE INSERM U1176 - PARIS-SACLAY 80 RUE DU GÉNÉRAL LECLERC 94276 LE KREMLIN-BICETRE 94276
LENTING PETRUS INSERM U1176 - PARIS-SACLAY 80 RUE DU GÉNÉRAL LECLERC 94276 KREMLIN-BICÊTRE 94276

Cited Art Landscape

Load Citation